Survodutide 化學(xué)特性,用途語(yǔ),生産方法
使用
Survodutide is a dual glucagon/glucagon-like peptide 1 (GLP1) receptor agonist. Survodutide has demonstrated blood sugar lowering efficacy in a Phase II trial for the treatment of patients with type 2 diabetes and obesity and was associated with clinically meaningful weight loss
[1]. Survodutide is also being studied for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)
[2].
參考文獻(xiàn)
[1] BRIAND F, AUGUSTIN R, WESCHE F, et al. 1635-P: Survodutide Weight Loss Is Associated with Changes in Food Preference and Improvement of Dyslipidemia in the Free Choice Diet–Induced Obese Hamster Model[J]. Diabetes, 2024, 33 2. DOI:10.2337/db24-1635-p.
[2] Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis[J]. Journal of Hepatology, 2024, 81 5: Pages 837-846. DOI:10.1016/j.jhep.2024.06.003.
Survodutide 上流と下流の製品情報(bào)
原材料
準(zhǔn)備製品